3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
265
Leukemia, Lymphocytic, Chronic, B-Cell
66
Lymphoma, Large B-Cell, Diffuse
60
Neoplasms, Plasma Cell
50
Lymphoma, Follicular
45
Lymphoma, Mantle-Cell
42
Lymphoma
41
Recurrence
38
Lymphoma, B-Cell, Marginal Zone
31
Leukemia
30
Leukemia, Myeloid, Acute
27
Lymphoma, B-Cell
19
Lymphoma, Non-Hodgkin
17
Myelodysplastic Syndromes
16
Waldenstrom Macroglobulinemia
15
Smoldering Multiple Myeloma
13
Hodgkin Disease
13
Lymphoma, T-Cell, Peripheral
12
Neoplasms
11
Lymphoma, T-Cell
9
Prostatic Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell, Cutaneous
8
Immunoglobulin Light-chain Amyloidosis
8
Burkitt Lymphoma
8
Sezary Syndrome
7
Neoplasm, Residual
7
Mycosis Fungoides
7
Lymphoma, Large-Cell, Anaplastic
7
Leukemia, Plasma Cell
6
Interventions
Dexamethasone
10
Cyclophosphamide
9
Cytarabine
7
venetoclax
6
Vincristine
6
Methotrexate
5
blinatumomab
4
Prednisone
4
Inotuzumab Ozogamicin
4
Doxorubicin
4
Rituximab
3
prednylidene
2
pegaspargase
2
merphos
2
dexamethasone acetate
2
dexamethasone 21-phosphate
2
deltacortene
2
Mercaptopurine
2
Etoposide
2
Decitabine
2
Calcium Dobesilate
2
trametinib
1
ruxolitinib
1
olverembatinib
1
ofatumumab
1
nilotinib
1
navitoclax
1
fludarabine
1
capivasertib
1
azathiopurine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
×
Lenalidomide
×
Clear all
NCT01116193
2017-09-14
RV-405 LAL
Institut de Cancérologie de la Loire
Phase 2
Completed
10 enrolled